ArticleThe Journal of infectious diseases2019
Evaluation of TypeSeq, a Novel High-Throughput, Low-Cost, Next-Generation Sequencing-Based Assay for Detection of 51 Human Papillomavirus Genotypes.
Article in The Journal of infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial.The Lancet. Oncology · 2020Trial
- Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial.Journal of the National Cancer Institute · 2020Trial
- Durability of Cross-Protection by Different Schedules of the Bivalent HPV Vaccine: The CVT Trial.Journal of the National Cancer Institute · 2020Trial
- Validation of TypeSeq2, a Next-Generation-Based Sequencing Assay for the Detection of 46 Human Papillomavirus Genotypes, at the US National Cancer Institute and Costa Rica Laboratories.The Journal of infectious diseases · 2025Article
- Associations among HPV persistence, the vaginal microbiome, and cervical cancer recurrence.Journal of translational medicine · 2025Article
- A Direct Comparative Analysis of HPV DNA with Single-Molecule RNA and p16JID innovations : skin science from molecules to population health · 2025Article
- Article
- HPV-KITE: sequence analysis software for rapid HPV genotype detection.Briefings in bioinformatics · 2025Article
- Multimodal assessment of high-risk human papillomavirus in sinonasal squamous cell carcinoma.Pathology, research and practice · 2024Article
- Article
- Differential long-term bivalent HPV vaccine cross-protection by variants in the Costa Rica HPV vaccine trial.NPJ vaccines · 2024Article
- A rapid HPV typing assay to support global cervical cancer screening and risk-based management: A cross-sectional study.International journal of cancer · 2024Article
- Different human papillomavirus types share early natural history transitions in immunocompetent women.International journal of cancer · 2022Article
- Performance of Cervical Screening a Decade Following HPV Vaccination: The Costa Rica Vaccine Trial.Journal of the National Cancer Institute · 2022Article
- Head-to-head comparison of 7 high-sensitive human papillomavirus nucleic acid detection technologies with the SPF10 LiPA-25 system.Journal of the National Cancer Center · 2022Article
- Analysis of cervical HPV infections among unvaccinated young adult women to inform vaccine strategies in this age group: the Costa Rica HPV Vaccine Trial.Sexually transmitted infections · 2022Article
- Article
- Age-specific prevalence of human papillomavirus and abnormal cytology at baseline in a diverse statewide prospective cohort of individuals undergoing cervical cancer screening in Mississippi.Cancer medicine · 2021Article
- Risk Factors for Non-Human Papillomavirus (HPV) Type 16/18 Cervical Infections and Associated Lesions Among HPV DNA-Negative Women Vaccinated Against HPV-16/18 in the Costa Rica Vaccine Trial.The Journal of infectious diseases · 2021Article
- NanoString Technology for Human Papillomavirus Typing.Viruses · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
backgroundHuman papillomaviruses (HPV) cause over 500 000 cervical cancers each year, most of which occur in low-resource settings. Human papillomavirus genotyping is important to study natural history and vaccine efficacy. We evaluated TypeSeq, a novel, next-generation, sequencing-based assay that detects 51 HPV genotypes, in 2 large international epidemiologic studies.
methodsTypeSeq was evaluated in 2804 cervical specimens from the Study to Understand Cervical Cancer Endpoints and Early Determinants (SUCCEED) and in 2357 specimens from the Costa Rica Vaccine Trial (CVT). Positive agreement and risks of precancer for individual genotypes were calculated for TypeSeq in comparison to Linear Array (SUCCEED). In CVT, positive agreement and vaccine efficacy were calculated for TypeSeq and SPF10-LiPA.
resultsWe observed high overall and positive agreement for most genotypes between TypeSeq and Linear Array in SUCCEED and SPF10-LiPA in CVT. There was no significant difference in risk of precancer between TypeSeq and Linear Array in SUCCEED or in estimates of vaccine efficacy between TypeSeq and SPF10-LiPA in CVT.
conclusionsThe agreement of TypeSeq with Linear Array and SPF10-LiPA, 2 well established standards for HPV genotyping, demonstrates its high accuracy. TypeSeq provides high-throughput, affordable HPV genotyping for world-wide studies of cervical precancer risk and of HPV vaccine efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.